Posted by Michael Wonder on 23 Aug 2021
TGA grants provisional determination to Celltrion Healthcare's anti-viral COVID-19 treatment regdanvimab
23 August 2021 - On 20 August 2021 the TGA granted provisional determination to Celltrion Healthcare in relation to regdanvimab.
This monoclonal antibody treatment is now eligible to be considered by the TGA for treatment of mild to moderate COVID-19 in adults who are confirmed to be infected with SARS-CoV-2.
